Welcome to LookChem.com Sign In|Join Free
  • or
D-Lysine is the unnatural isomer of L-Lysine, an essential amino acid that plays a crucial role in various biological processes. Unlike L-Lysine, D-Lysine has unique properties and potential applications in different industries.

923-27-3

Post Buying Request

923-27-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

923-27-3 Usage

Uses

Used in Pharmaceutical Industry:
D-Lysine is used as a potential polymeric drug carrier due to its ability to form polypeptide chains of poly-D-lysine, which act as nonspecific adhesion-promoting molecules. This property allows for the development of innovative drug delivery systems and targeted therapies.
Used in Medical Research:
D-Lysine is used as a research tool in the study of non-enzymatic glycation, a process that contributes to the development of chronic diseases such as diabetes and aging. By reducing non-enzymatic glycation in vitro, D-Lysine can help researchers better understand the underlying mechanisms and develop potential therapeutic interventions.

Check Digit Verification of cas no

The CAS Registry Mumber 923-27-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,2 and 3 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 923-27:
(5*9)+(4*2)+(3*3)+(2*2)+(1*7)=73
73 % 10 = 3
So 923-27-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m1/s1

923-27-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name D-lysine

1.2 Other means of identification

Product number -
Other names Benzonitrile,2,6-diamino

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:923-27-3 SDS

923-27-3Synthetic route

C43H37ClN4NiO3

C43H37ClN4NiO3

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With hydrogenchloride In methanol; water at 40℃; for 4h;96%
C43H37ClN4NiO3

C43H37ClN4NiO3

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With hydrogenchloride In methanol; water at 40℃; for 4h;93%
N2,N6-dihexanoyl-DL-lysine
103678-51-9

N2,N6-dihexanoyl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
Conditions
ConditionsYield
With (-)-(R,R)-dibenzoyltartaric acid
With N-acetyl-3,5-dibromo-D-tyrosine
Enzymatische Herstellung;
N2,N6-bis-chloroacetyl-DL-lysine
53510-89-7

N2,N6-bis-chloroacetyl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
N6-benzoyl-D-lysine
132983-06-3

N6-benzoyl-D-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With hydrogenchloride Hydrolysis;
N-ε-benzyloxycarbonyl lysine
32302-83-3

N-ε-benzyloxycarbonyl lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
N2-acetyl-N6-benzoyl-DL-lysine
3066-80-6

N2-acetyl-N6-benzoyl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
N6-benzoyl-N2-chloroacetyl-DL-lysine
109454-36-6

N6-benzoyl-N2-chloroacetyl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
N6-benzoyl-N2-butyryl-DL-lysine
109036-22-8

N6-benzoyl-N2-butyryl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Mikrobiologische Herstellung;
5-(4-aminobutyl)-hydantoin
29070-06-2

5-(4-aminobutyl)-hydantoin

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With potassium phosphate buffer; Pseudomonas sp. AJ-11220 In various solvent(s) at 30℃; for 2h; pH 8.0; enzymatic reaction;
With potassium phosphate buffer; Pseudomonas sp. AJ-11220 In various solvent(s) at 30℃; for 2h;
Fmoc-Lys(tert-butoxycarbonyl)
71989-26-9

Fmoc-Lys(tert-butoxycarbonyl)

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With p-benzyloxybenzylalcohol resin; dmap; dicyclohexyl-carbodiimide Product distribution; Ambient temperature; examination of attachment to polymers and racemization;3.8 % Chromat.
l-menthyl 5-cyano-2-hydroxyiminovalerate
111491-65-7

l-menthyl 5-cyano-2-hydroxyiminovalerate

A

D-lysine
923-27-3

D-lysine

B

L-lysine
56-87-1

L-lysine

Conditions
ConditionsYield
With hydrogenchloride; potassium hydroxide; hydrogen; acetic anhydride; nickel 1.) atmospheric pressure, t-butyl alcohol; Yield given. Multistep reaction. Title compound not separated from byproducts;
N2,N6-diacetyl-DL-lysine

N2,N6-diacetyl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
N2,N6-dibenzoyl-DL-lysine

N2,N6-dibenzoyl-DL-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Enzymatische Herstellung;
N6-benzoyl-lysine
5107-18-6

N6-benzoyl-lysine

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aqueous NaOH
2: Enzymatische Herstellung
View Scheme
(2R,6R)-2,6-diaminoheptanedioic acid
583-93-7, 922-54-3, 2577-62-0, 14289-34-0, 17121-19-6

(2R,6R)-2,6-diaminoheptanedioic acid

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With diaminopimelate decarboxylase from Mycobacterium tuberculosis; pyridoxal 5'-phosphate; potassium chloride; triethylamine at 25℃; Kinetics; Enzymatic reaction;
aplysinellamide A 2,2,2-trifluoroacetate

aplysinellamide A 2,2,2-trifluoroacetate

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With hydrogenchloride; water at 110℃; for 20h;
thalassosamide

thalassosamide

D-lysine
923-27-3

D-lysine

Conditions
ConditionsYield
With hydrogen iodide at 110℃; for 18h;
ethyl (E)-2-((tert-butoxycarbonyl)amino)-5-cyano-3-fluoropent-4-enoate

ethyl (E)-2-((tert-butoxycarbonyl)amino)-5-cyano-3-fluoropent-4-enoate

A

D-lysine
923-27-3

D-lysine

B

2,6-diamino-3-fluorohexanoic acid dihydrochloride

2,6-diamino-3-fluorohexanoic acid dihydrochloride

Conditions
ConditionsYield
Stage #1: ethyl (E)-2-((tert-butoxycarbonyl)amino)-5-cyano-3-fluoropent-4-enoate With hydrogenchloride; hydrogen In ethanol for 1h;
Stage #2: In water Reflux;
ethyl (E)-2-(((benzyloxy)carbonyl)amino)-5-cyano-3-fluoropent-4-enoate

ethyl (E)-2-(((benzyloxy)carbonyl)amino)-5-cyano-3-fluoropent-4-enoate

A

D-lysine
923-27-3

D-lysine

B

2,6-diamino-3-fluorohexanoic acid dihydrochloride

2,6-diamino-3-fluorohexanoic acid dihydrochloride

Conditions
ConditionsYield
Stage #1: ethyl (E)-2-(((benzyloxy)carbonyl)amino)-5-cyano-3-fluoropent-4-enoate With hydrogenchloride; hydrogen In ethanol for 1h;
Stage #2: In water Reflux;
D-lysine
923-27-3

D-lysine

pipecolinic acid
3105-95-1

pipecolinic acid

Conditions
ConditionsYield
With porcine kidney D-amino acid oxidase; Pseudomonas putida N-methyl-L-amino acid dehydrogenase; Tris buffer; flavin adenine dinucleotide; catalase In various solvent(s) at 30℃; for 24h; pH=5.1 - 7.6;100%
D-lysine
923-27-3

D-lysine

di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

Boc-D-Lys(Boc)-OH
65360-27-2

Boc-D-Lys(Boc)-OH

Conditions
ConditionsYield
With sodium hydroxide In 1,4-dioxane97%
D-lysine
923-27-3

D-lysine

(R)-3-amino-azepan-2-one
28957-33-7

(R)-3-amino-azepan-2-one

Conditions
ConditionsYield
With chloro-trimethyl-silane; 1,1,1,3,3,3-hexamethyl-disilazane In xylene95%
With pyridine In ethylene glycol for 1h; Microwave irradiation;82%
In ethylene glycol for 1h; Microwave irradiation;82%
Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran; water for 3h;94.6%
methanol
67-56-1

methanol

D-lysine
923-27-3

D-lysine

D-lysine methyl ester
687-64-9, 42807-32-9, 44977-95-9

D-lysine methyl ester

Conditions
ConditionsYield
With hydrogenchloride; 2,2-dimethoxy-propane93%
D-lysine
923-27-3

D-lysine

benzyl chloroformate
501-53-1

benzyl chloroformate

(R)-2-amino-6-(((benzyloxy)carbonyl)amino)hexanoic acid
34404-32-5, 1155-64-2, 32302-83-3

(R)-2-amino-6-(((benzyloxy)carbonyl)amino)hexanoic acid

Conditions
ConditionsYield
Stage #1: D-lysine With copper(II) sulfate; sodium hydroxide In water at 20℃; for 5h;
Stage #2: benzyl chloroformate With ethylenediaminetetraacetic acid at 20℃; for 3h;
91%
methanol
67-56-1

methanol

D-lysine
923-27-3

D-lysine

D-lysine methyl ester bis-hydrochloride

D-lysine methyl ester bis-hydrochloride

Conditions
ConditionsYield
With hydrogenchloride87%
D-lysine
923-27-3

D-lysine

tetrabutylammonium 1-{4-[(2,2-dioxido-1,2-oxathiolan-3-yl)methyl]phenyl}-4-fluorobutane-2-sulfonate
1344707-94-3

tetrabutylammonium 1-{4-[(2,2-dioxido-1,2-oxathiolan-3-yl)methyl]phenyl}-4-fluorobutane-2-sulfonate

tetrabutylammonium 1-(4-{4-[(5-amino-5-carboxypentyl)amino]-2-sulfobutyl}phenyl)-4-fluorobutane-2-sulfonate
1344707-99-8

tetrabutylammonium 1-(4-{4-[(5-amino-5-carboxypentyl)amino]-2-sulfobutyl}phenyl)-4-fluorobutane-2-sulfonate

Conditions
ConditionsYield
In water; acetonitrile at 20℃; for 24h;82%
D-lysine
923-27-3

D-lysine

4-methyl cinnamate-4', 4''-di(formylphenyl)amine

4-methyl cinnamate-4', 4''-di(formylphenyl)amine

4-methyl cinnamate-4',4''-di((E)-2-amino-6-(benzylideneamino)hexanoic acid)

4-methyl cinnamate-4',4''-di((E)-2-amino-6-(benzylideneamino)hexanoic acid)

Conditions
ConditionsYield
With potassium hydroxide In methanol for 12h; Reflux;81.9%
D-lysine
923-27-3

D-lysine

atorvastatin
134523-00-5

atorvastatin

(3R,5R)-7-[3-phenyl-4-[(phenylamino)carbonyl]-2-(4-fluorophenyl)-5-(1-methyl-ethyl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid D-lysine salt
609843-25-6

(3R,5R)-7-[3-phenyl-4-[(phenylamino)carbonyl]-2-(4-fluorophenyl)-5-(1-methyl-ethyl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid D-lysine salt

Conditions
ConditionsYield
In ethyl acetate at 20℃; for 20h;76%
D-lysine
923-27-3

D-lysine

phenethylamine
64-04-0

phenethylamine

2-benzothiazolyl 2-methanesulfonoxyethyl disulfide
183056-94-2

2-benzothiazolyl 2-methanesulfonoxyethyl disulfide

2-bromo-3-(1H-indol-3-yl)-propionic acid

2-bromo-3-(1H-indol-3-yl)-propionic acid

(2S,5R)-5-(4-Amino-butyl)-2-(1H-indol-3-ylmethyl)-7-phenethyl-[1,4,7]thiadiazonane-3,6-dione

(2S,5R)-5-(4-Amino-butyl)-2-(1H-indol-3-ylmethyl)-7-phenethyl-[1,4,7]thiadiazonane-3,6-dione

Conditions
ConditionsYield
Multistep reaction;74%
aminomethyl-terminated Tentagel resin

aminomethyl-terminated Tentagel resin

D-Alanine
338-69-2

D-Alanine

L-valine
72-18-4

L-valine

L-leucine
61-90-5

L-leucine

D-lysine
923-27-3

D-lysine

N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine
35661-39-3

N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine

Boc-Ala-[4-(oxymethyl)phenylacetic acid]

Boc-Ala-[4-(oxymethyl)phenylacetic acid]

L-cyclohexylalanine
27527-05-5

L-cyclohexylalanine

Fmoc-Ser(tBu)-OH
71989-33-8

Fmoc-Ser(tBu)-OH

Fmoc-(tBu)Asp-OH
71989-14-5

Fmoc-(tBu)Asp-OH

Fmoc-Thr(tBu)-OH
71989-35-0

Fmoc-Thr(tBu)-OH

(2S)-N-allyloxycarbonyl-L-proline
110637-44-0

(2S)-N-allyloxycarbonyl-L-proline

Fmoc-His(Trt)-OH
109425-51-6

Fmoc-His(Trt)-OH

glycine
56-40-6

glycine

2,2-dimethoxyethylamine
22483-09-6

2,2-dimethoxyethylamine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

L-Tryptophan
73-22-3

L-Tryptophan

C146H237N41O42
1616473-97-2

C146H237N41O42

Conditions
ConditionsYield
Stage #1: aminomethyl-terminated Tentagel resin; Boc-Ala-[4-(oxymethyl)phenylacetic acid] With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 3h; aminomethyl polyethylene glycol polyacrylamide resin; Automated synthesizer;
Stage #2: With trifluoroacetic acid In dichloromethane; N,N-dimethyl-formamide for 0.5h; aminomethyl polyethylene glycol polyacrylamide resin; Automated synthesizer;
Stage #3: D-Alanine; L-valine; L-leucine; D-lysine; N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine; L-cyclohexylalanine; Fmoc-Ser(tBu)-OH; Fmoc-(tBu)Asp-OH; Fmoc-Thr(tBu)-OH; (2S)-N-allyloxycarbonyl-L-proline; Fmoc-His(Trt)-OH; glycine; 2,2-dimethoxyethylamine; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; L-Tryptophan Further stages;
68%
Stage #1: aminomethyl-terminated Tentagel resin; Boc-Ala-[4-(oxymethyl)phenylacetic acid] With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 3h; aminomethyl polyethylene glycol polyacrylamide resin; Automated synthesizer;
Stage #2: With trifluoroacetic acid In dichloromethane; N,N-dimethyl-formamide for 0.5h; aminomethyl polyethylene glycol polyacrylamide resin; Automated synthesizer;
Stage #3: D-Alanine; L-valine; L-leucine; D-lysine; N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine; L-cyclohexylalanine; Fmoc-Ser(tBu)-OH; Fmoc-(tBu)Asp-OH; Fmoc-Thr(tBu)-OH; (2S)-N-allyloxycarbonyl-L-proline; Fmoc-His(Trt)-OH; glycine; 2,2-dimethoxyethylamine; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; L-Tryptophan Further stages;
65%
sodium molybdate dihydrate
7631-95-0

sodium molybdate dihydrate

D-lysine
923-27-3

D-lysine

Na2[Mo8O26(D-lysine)2] octahydrate

Na2[Mo8O26(D-lysine)2] octahydrate

Conditions
ConditionsYield
With HClO4 In water 25°C, pH = 3 (HClO4), pptn.; recrystn. (H2O, 70°C), filtration, drying (room temp.);27%
2-(methylthio)-1,4,5,6-tetrahydropyrimidine
20112-81-6

2-(methylthio)-1,4,5,6-tetrahydropyrimidine

D-lysine
923-27-3

D-lysine

di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

Nα-(tert-butoxycarbonyl)-NG,NG'-propano-D-homoarginine

Nα-(tert-butoxycarbonyl)-NG,NG'-propano-D-homoarginine

Conditions
ConditionsYield
With sodium hydroxide; magnesium oxide 1.) CH2Cl2, 60 deg C, overnight, pH=10.65, 2.) CH2Cl2, dioxane, RT, 20 h, pH=10; Yield given. Multistep reaction;
N,N'-diethyl-S-methyl-isothiourea
161331-40-4

N,N'-diethyl-S-methyl-isothiourea

D-lysine
923-27-3

D-lysine

di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

A

Nα-(tert-butoxycarbonyl)-NG,NG'-diethyl-D-homoarginine
110798-07-7

Nα-(tert-butoxycarbonyl)-NG,NG'-diethyl-D-homoarginine

B

Boc-D-Lys(Boc)-OH
65360-27-2

Boc-D-Lys(Boc)-OH

Conditions
ConditionsYield
With sodium hydroxide; magnesium oxide 1.) CH2Cl2, 60 deg C, overnight, pH=10.65, 2.) CH2Cl2, dioxane, RT, 20 h, pH=10; Yield given. Multistep reaction;
D-lysine
923-27-3

D-lysine

N-butyl-S-methyl-isothiourea
100319-25-3

N-butyl-S-methyl-isothiourea

di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

Nα-(tert-butoxycarbonyl)-NG-n-butyl-D-homoarginine

Nα-(tert-butoxycarbonyl)-NG-n-butyl-D-homoarginine

Conditions
ConditionsYield
With sodium hydroxide; magnesium oxide 1.) CH2Cl2, 60 deg C, overnight, pH=10.65, 2.) CH2Cl2, dioxane, RT, 20 h, pH=10; Yield given. Multistep reaction;
D-lysine
923-27-3

D-lysine

(+/-)-2-<3-(4-chlorobenzoyl)-2-methylphenoxy>propionic acid
74168-08-4

(+/-)-2-<3-(4-chlorobenzoyl)-2-methylphenoxy>propionic acid

(+)-2-<3-(4-chlorobenzoyl)-2-methylphenoxy>propionate of D-lysine

(+)-2-<3-(4-chlorobenzoyl)-2-methylphenoxy>propionate of D-lysine

Conditions
ConditionsYield
In methanol; water

923-27-3Relevant academic research and scientific papers

Preparation and characterization of a new open-tubular capillary column for enantioseparation by capillary electrochromatography

Li, Yingjie,Tang, Yimin,Qin, Shili,Li, Xue,Dai, Qiang,Gao, Lidi

, p. 283 - 292 (2019/02/05)

In order to use the enantioseparation capability of cationic cyclodextrin and to combine the advantages of capillary electrochromatography (CEC) with open-tubular (OT) column, in this study, a new OT-CEC, coated with cationic cyclodextrin (1-allylimidazolium-β-cyclodextrin [AI-β-CD]) as chiral stationary phase (CSP), was prepared and applied for enantioseparation. Synthesized AI-β-CD was characterized by infrared (IR) spectrometry and mass spectrometry (MS). The preparation conditions for the AI-β-CD-coated column were optimized with the orthogonal experiment design L9(34). The column prepared was characterized by scanning electron microscopy (SEM) and elemental analysis (EA). The results showed that the thickness of stationary phase in the inner surface of the AI-β-CD-coated columns was about 0.2 to 0.5?μm. The AI-β-CD content in stationary phase based on the EA was approximately 2.77?mmol·m?2. The AI-β-CD-coated columns could separate all 14 chiral compounds (histidine, lysine, arginine, glutamate, aspartic acid, cysteine, serine, valine, isoleucine, phenylalanine, salbutamol, atenolol, ibuprofen, and napropamide) successfully in the study and exhibit excellent reproducibility and stability. We propose that the column, coated with AI-β-CD, has a great potential for enantioseparation in OT-CEC.

Chiral Metal–Organic Framework Hollow Nanospheres for High-Efficiency Enantiomer Separation

Wang, Xiaoshi,Zhu, Yanan,Liu, Jian,Liu, Chang,Cao, Changyan,Song, Weiguo

, p. 1535 - 1538 (2018/06/26)

Chiral ZIF-8 hollow nanospheres with d-histidine as part of chiral ligands (denoted as H-d-his-ZIF-8) were prepared for separation of (±)-amine acids. Compared to bulk d-his-ZIF-8 without a hollow cavity, the prepared H-d-his-ZIF-8 showed 15 times higher separation capacity and higher ee values of 90.5 % for alanine, 95.2 % for glutamic acid and 92.6 % for lysine, respectively.

Covalent Organic Frameworks with Chirality Enriched by Biomolecules for Efficient Chiral Separation

Zhang, Sainan,Zheng, Yunlong,An, Hongde,Aguila, Briana,Yang, Cheng-Xiong,Dong, Yueyue,Xie, Wei,Cheng, Peng,Zhang, Zhenjie,Chen, Yao,Ma, Shengqian

supporting information, p. 16754 - 16759 (2018/11/27)

The separation of racemic compounds is important in many fields, such as pharmacology and biology. Taking advantage of the intrinsically strong chiral environment and specific interactions featured by biomolecules, here we contribute a general strategy is developed to enrich chirality into covalent organic frameworks (COFs) by covalently immobilizing a series of biomolecules (amino acids, peptides, enzymes) into achiral COFs. Inheriting the strong chirality and specific interactions from the immobilized biomolecules, the afforded biomolecules?COFs serve as versatile and highly efficient chiral stationary phases towards various racemates in both normal and reverse phase of high-performance liquid chromatography (HPLC). The different interactions between enzyme secondary structure and racemates were revealed by surface-enhanced Raman scattering studies, accounting for the observed chiral separation capacity of enzymes?COFs.

Stereospecific radiosynthesis of 3-fluoro amino acids: Access to enantiomerically pure radioligands for positron emission tomography

Alluri, Santosh R.,Riss, Patrick J.

supporting information, p. 2219 - 2224 (2018/04/05)

A variety of substituted non-racemic aziridine-2-carboxylates equivalent to amino acids were prepared and subjected to ring opening reaction by [18F/19F]fluoride. The regio and stereospecific ring opening depends on the substituents on the nitrogen as well as both the carbons of aziridines. The applicability of the methods to afford access to 3-[18F/19F]fluoro amino acids are illustrated.

Chromatographic Resolution of α-Amino Acids by (R)-(3,3'-Halogen Substituted-1,1'-binaphthyl)-20-crown-6 Stationary Phase in HPLC

Wu, Peng,Wu, Yuping,Zhang, Junhui,Lu, Zhenyu,Zhang, Mei,Chen, Xuexian,Yuan, Liming

supporting information, p. 1037 - 1042 (2017/07/25)

Three new chiral stationary phases (CSPs) for high-performance liquid chromatography were prepared from R-(3,3'-halogen substituted-1,1'-binaphthyl)-20-crown-6 (halogen = Cl, Br and I). The experimental results showed that R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6 (CSP-1) possesses more prominent enantioselectivity than the two other halogen-substituted crown ether derivatives. All twenty-one α-amino acids have different degrees of separation on R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6-based CSP-1 at room temperature. The enantioselectivity of CSP-1 is also better than those of some commercial R-(1,1'-binaphthyl)-20-crown-6 derivatives. Both the separation factors (α) and the resolution (Rs) are better than those of commercial crown ether-based CSPs [CROWNPAK CR(+) from Daicel] under the same conditions for asparagine, threonine, proline, arginine, serine, histidine and valine, which cannot be separated by commercial CR(+). This study proves the commercial usefulness of the R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6 chiral stationary phase.

Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris

Zhang, Fan,Barns, Kenneth,Hoffmann, F. Michael,Braun, Doug R.,Andes, David R.,Bugni, Tim S.

, p. 2551 - 2555 (2017/09/27)

Here we describe the rapid identification and prioritization of novel active marine natural products using an improved dereplication strategy. During the course of our screening of marine natural product libraries, a new cyclic trihydroxamate compound, thalassosamide, was discovered from the α-proteobacterium Thalassospira profundimaris. Its structure was determined by 2D NMR and MS/MS experiments, and the absolute configuration of the lysine-derived units was established by Marfey's analysis, whereas that of C-9, 9′, and 9″ was determined via the circular dichroism data of the [Rh2(OCOCF3)4] complex and DFT NMR calculations. Thalassosamide showed moderate in vivo efficacy against Pseudomonas aeruginosa.

A method for preparing DL-lysine

-

Paragraph 0032; 0033, (2017/04/03)

The invention provides a method for preparing DL-lysine with chiral lysine salt as a raw material. The method specifically comprises the following steps: dissolving chiral lysine salt in an acetic acid water solution, adding salicylaldehyde or benzaldehyde as a catalyst, carrying out heating and racemization, removing solvents through vacuum distillation after racemization is completed, washing a residual solid with ethanol, obtaining DL-lysine salt, removing salt with an ion exchange column and carrying out concentration and decoloration, thus obtaining a DL-lysine solid. The preparation method has the advantages that the preparation method is lower in production cost and simple in process; pollution is not easily caused in the production process; the racemization rate of L-lysine hydrochloride can be 100%; the purity of the obtained DL-lysine finished product is more than 98%.

COMPOSITIONS AND METHODS FOR THE PREPARATION OF KIDNEY PROTECTIVE AGENTS COMPRISING AMIFOSTINE AND AMINO ACIDS

-

, (2016/06/13)

This invention relates to composition and method of preparation of AminoMedix? comprising of Amifostine, at least one amino acid (Arginine, Lysine, Histidine) with or without other pharmaceutically active compounds. The AminoMedix? composition can be applied for kidney protection during therapy using radiolabeled and non-radiolabeled compounds, contrast agents, chemotherapeutics, antibiotics and drugs showing nephrotoxic effect.

AXIAL-ASYMMETRIC N-(2-ACYLARYL)-2-[5, 7-DIHYDRO-6H-DIBENZO [C, E] AZEPINE-6-YL] ACETAMIDE COMPOUND AND CHIRALITY CONVERSION METHOD FOR A-AMINO ACID USING SAME

-

Paragraph 0152; 0153; 0154, (2015/11/27)

An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method. The present invention provides an N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl]ac etamide compound represented by Formula (1): or a salt thereof, or a metal complex represented by Formula (3) :

Chemical dynamic kinetic resolution and S/R interconversion of unprotected α-amino acids

Takeda, Ryosuke,Kawamura, Akie,Kawashima, Aki,Sato, Tatsunori,Moriwaki, Hiroki,Izawa, Kunisuke,Akaji, Kenichi,Wang, Shuni,Liu, Hong,Ace?a, José Luis,Soloshonok, Vadim A.

supporting information, p. 12214 - 12217 (2016/02/18)

Reported herein is the first purely chemical method for the dynamic kinetic resolution (DKR) of unprotected racemic α-amino acids (α-AAs), a method which can rival the economic efficiency of the enzymatic reactions. The DKR reaction principle can be readily applied for S/R interconversions of α-AAs, the methodological versatility of which is unmatched by biocatalytic approaches. The presented process features a virtually complete stereochemical outcome, fully recyclable source of chirality, and operationally simple and convenient reaction conditions, thus allowing its ready scalability. A quite unique and novel mode of the thermodynamic control over the stereochemical outcome, including an exciting interplay between axial, helical, and central elements of chirality is proposed. A new player for DKR: Dynamic kinetic resolution of α-amino acids has been achieved upon complexation with nickel(II) and a chiral ligand derived from optically active bis(naphthyl)amine under thermodynamic control, thus affording excellent diastereoselectivities and chemical yields. The S to R interconversion of α-amino acids is also described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 923-27-3